阿德福维尔抗癌潜力:HeLa细胞中的网络药理学,抗增殖和亡作用
Muzammal Mateen Azhar1, Tahir Maqbool1, Fatima Ali1
1Centre for Research in Molecular Medicine, Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
Biomolecules & biomedicine
|March 19, 2025
概括
阿德福维尔在治疗子宫癌方面表现有前途,通过向多个途径,诱导亡,并抑制HeLa细胞的增殖. 这种药物具有较低的毒性,并在临床前研究中表现优于5-Fluorouracil.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
背景情况:
- 宫癌复发和耐药性需要新的治疗策略.
- 网络药理学提供了一种方法,通过识别多目标机制来重新利用药物.
- 作为一种非循环核酸模拟剂的阿德福维尔显示出对宫癌治疗的潜力,特别是在HeLa细胞中.
研究的目的:
- 通过结合网络药理学和体外方法,研究阿德福维尔对宫癌的分子机制.
- 预测和验证阿德福维尔的基因标,并评估其与关键蛋白质的结合亲和力.
- 评估阿德福维尔在抑制HeLa细胞增殖和诱导亡方面的体外疗效.
主要方法:
- 网络药理学分析以确定阿德福维尔和宫癌之间的共同目标.
- 蛋白质与蛋白质相互作用网络的构建和枢纽目标的识别.
- 分子对接以评估阿德福维尔与标蛋白 (MAPK3,SRC) 的结合亲和力.
- 在体外测试 (MTT,水晶紫色,p53 ELISA,VEGF ELISA) 来评估HeLa细胞中的细胞毒性,增殖,亡和VEGF水平.
主要成果:
- 确定了阿德福维尔和宫癌之间的144个共同目标,其中瘤性途径的关键枢纽目标.
- 分子对接证实了阿德福维尔与MAPK3和SRC的强度结合.
- 在体外研究表明,阿德福维尔显著抑制了HeLa细胞活力 (IC50 = 7.8μM),表现优于5-Fluorouracil.
- 阿德福维尔通过p53激活诱导了细胞亡,并通过抑制VEGF抑制细胞增殖.
结论:
- 阿德福维尔通过包括诱导亡和抑制扩散在内的机制对宫癌产生多重向作用.
- 该药物表现出有希望的临床前疗效,具有有利的安全性.
- 阿德福维尔值得进一步研究,作为宫癌的潜在替代治疗剂.
相关概念视频
02:49Cancer Therapies
7.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:34Inhibition of Cdk Activity
4.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.5K